Pharmaceutical

Dr. Reddy's Q1 2025 Financial report Market Trend Financial statements Dr. Reddy Dr. Reddy's FY2024 revenue rose 17% to $3.81B, driven by strong generics, strategic acquisitions, and a focus on OTC and healthcare. Net profit grew 2.8% as the company expanded globally.
Semaglutide vs Tirzepatide in Weight Loss Semaglutide Tirzepatide Novo Nordisk Eli Lilly A head-to-head clinical trial shows Tirzepatide significantly outperforms Semaglutide in weight loss and waist reduction among obese non-diabetic adults, with superior efficacy and comparable safety.
ChongKunDang Acquires 7% Stake in AbClon to Co-Develop CD19 CAR-T Therapy Chong Kun Dang ChongKunDang acquires a 7.33% stake in AbClon and partners to co-develop CD19 CAR-T therapy AT101. The deal boosts CGT innovation with plans for fast-track approval and global expansion.
Takeda Shuts Down EGFR, B7-H3 Programs Takeda Market Trend Takeda announces major R&D cuts, discontinuing EGFR and B7-H3 oncology projects from its $525M Maverick deal, and streamlining other pipelines to focus on high-potential therapies.
AACR 2025 China ADC Achievements Overview AACR ADC Explore key highlights from AACR 2025, where Chinese biotech firms showcased breakthroughs in ADC therapies, including dual-target, dual-payload innovations and promising clinical outcomes in solid tumor treatments.
Shionogi to Acquire Pharmaceutical Company for Nearly 8 Billion Yuan Shionogi Japanese pharma company Shionogi will acquire Torii Pharmaceutical from Japan Tobacco for ¥160 billion, expanding its portfolio in dermatology, nephrology, and global drug development.
Takeda's 2024 Q4 Financial report Market Trend Financial statements Takeda Takeda's 2024 fiscal report shows 7.4% revenue growth to ¥4.58T, driven by strong core business and R&D breakthroughs. Key segments include GI, rare diseases, oncology. Outlook for 2025 remains stable despite VYVANSE competition.
BeiGene's Q1 2025 Financial report Market Trend Financial statements BeiGene BeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
Novo Nordisk's Q1 2025 Financial report Market Trend Financial statements Novo Nordisk Novo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.
Meloxicam vs Ibuprofen Comparison Meloxicam Ibuprofen Meloxicam vs Ibuprofen: Meloxicam is a long-acting NSAID used for managing osteoarthritis and rheumatoid arthritis pain, while Ibuprofen provides quick relief for pain, inflammation, and fever. Learn which medication is best for your needs.